Karyopharm Therapeutics Income Statement (2012-2026)

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Jun2026
Revenue & cost
Revenue (Quarter)	22.60M	37.69M	126.27M	47.67M	39.68M	36.15M	33.58M	38.70M	37.58M	36.01M	33.75M	33.13M	42.79M	38.78M	30.54M	30.02M	37.93M	44.04M	34.08M	33.43M
Cost of Revenue (Quarter)	1.14M	0.59M	0.74M	1.43M	0.94M	0.98M	1.64M	1.35M	1.19M	0.91M	1.12M	1.91M	1.40M	1.24M	1.28M	1.30M	1.01M	2.11M	1.46M	1.08M
Gross Profit (Quarter)	21.46M	37.10M	125.53M	46.24M	38.74M	35.16M	31.94M	37.35M	36.38M	35.10M	32.63M	31.21M	41.38M	37.54M	29.26M	28.71M	36.91M	41.93M	32.62M	32.35M
Operating items
Research & Development (Quarter)	33.98M	45.81M	44.00M	42.06M	44.31M	31.36M	30.93M	32.34M	31.48M	35.55M	39.38M	35.42M	38.37M	36.13M	33.30M	34.62M	32.79M	30.54M	27.67M	28.96M
Selling, General & Administrative (Quarter)	36.53M	35.10M	34.56M	38.77M	37.34M	34.65M	34.65M	35.91M	34.48M	30.80M	30.69M	29.55M	31.07M	27.63M	27.19M	27.35M	28.48M	26.61M	22.77M	25.92M
Other Operating Expenses (Quarter)	1.14M	0.59M	0.74M	1.43M	0.94M	0.98M	1.87M	1.35M	1.19M	0.91M	1.49M	1.91M	1.47M	1.30M	1.33M	1.30M	1.05M	2.11M	1.48M	1.08M
Operating Expenses (Quarter)	71.65M	81.50M	79.31M	82.26M	82.59M	66.98M	67.45M	69.60M	67.15M	67.27M	71.56M	66.89M	70.91M	65.07M	61.82M	63.27M	62.32M	59.26M	51.92M	55.96M
Operating Income (Quarter)	-49.05M	-43.81M	46.96M	-34.59M	-42.91M	-30.84M	-33.87M	-30.90M	-29.57M	-31.26M	-37.81M	-33.76M	-28.12M	-26.28M	-31.28M	-33.26M	-24.39M	-15.22M	-17.84M	-22.53M
EBIT (Quarter)	-49.05M	-43.81M	46.96M	-34.59M	-42.91M	-30.84M	-33.87M	-30.90M	-29.57M	-31.26M	-37.81M	-33.76M	-28.12M	-26.28M	-31.28M	-33.26M	-24.39M	-15.22M	-17.84M	-22.53M
Non-operating items
Interest & Investment Income (Quarter)	0.17M	0.10M	0.06M	0.07M	0.29M	0.66M	1.33M	2.85M	2.82M	2.75M	2.52M	2.16M	1.93M	1.83M	1.48M	1.00M	0.61M	0.55M	0.61M	0.72M
Other Non Operating Income (Quarter)	0.44M	0.02M	-0.48M	-0.07M	-0.01M	0.02M	-0.01M	-0.26M		0.09M	-0.36M	0.20M	44.70M			19.82M			0.84M	-32.08M
Non Operating Income (Quarter)	-4.40M	-7.89M	-8.36M	-6.68M	-6.03M	-5.44M	-4.56M	-3.17M	-2.93M	-3.23M	-3.90M	-3.53M	51.98M	-5.76M	0.39M	9.83M	-12.82M	-17.87M	-84.42M	-44.50M
Net income details
EBT (Quarter)	-53.45M	-51.71M	38.60M	-41.27M	-48.94M	-36.28M	-39.33M	-34.07M	-32.50M	-34.49M	101.32M	-37.29M	23.86M	-32.04M	45.56M	-23.43M	-37.21M	-33.09M	90.12M	-67.02M
Tax Provisions (Quarter)	0.13M	0.11M	-0.12M	0.13M	0.12M	0.04M	0.10M	0.05M	0.13M	0.01M	0.13M	0.07M	0.07M	0.03M	-0.11M	0.04M	0.04M	0.03M	-41.27M
Profit After Tax (Quarter)	-53.58M	-51.81M	38.72M	-41.40M	-49.06M	-36.32M	-38.51M	-34.13M	-32.63M	-34.51M	-41.84M	-37.36M	23.79M	-32.07M	-30.78M	-23.46M	-37.25M	-33.13M	-102.20M	-67.02M
Income from Continuing Operations (Quarter)	-53.58M	-51.81M	38.72M	-41.40M	-49.06M	-36.32M	-39.43M	-34.13M	-32.63M	-34.51M	101.19M	-37.36M	23.79M	-32.07M	45.66M	-23.46M	-37.25M	-33.13M	131.39M	-67.02M
Consolidated Net Income (Quarter)	-53.58M	-51.81M	38.72M	-41.40M	-49.06M	-36.32M	-39.43M	-34.13M	-32.63M	-34.51M	101.19M	-37.36M	23.79M	-32.07M	45.66M	-23.46M	-37.25M	-33.13M	131.39M	-67.02M
Income towards Parent Company (Quarter)	-53.58M	-51.81M	38.72M	-41.40M	-49.06M	-36.32M	-39.43M	-34.13M	-32.63M	-34.51M	101.19M	-37.36M	23.79M	-32.07M	45.66M	-23.46M	-37.25M	-33.13M	131.39M	-67.02M
Net Income towards Common Stockholders (Quarter)	-53.58M	-51.81M	38.72M	-41.40M	-49.06M	-36.32M	-39.43M	-34.13M	-32.63M	-34.51M	101.19M	-37.36M	23.79M	-32.07M	45.66M	-23.46M	-37.25M	-33.13M	131.39M	-67.02M
Additional items
EPS (Basic) (Quarter)	-10.69	-10.30	7.72	-8.01	-9.24	-6.79	-7.22	-4.51	-4.29	-4.52	13.29	-4.85	2.95	-0.00M	0.01M	-0.00M	-0.00M	-0.00M	0.01M	-6.13
EPS (Diluted) (Quarter)	-10.69	-10.30	7.72	-8.01	-9.24	-6.79	-7.22	-4.51	-4.29	-4.52	13.29	-4.85	2.31	-0.00M	0.01M	-0.00M	-0.00M	-0.00M	0.01M	-6.13
Shares Outstanding (Quarter)	5.01M	5.03M	5.01M	5.17M	5.31M	5.35M	5.46M	7.57M	7.61M	7.63M	7.62M	7.70M	8.07M	0.01M	0.01M	0.01M	0.01M	0.01M	0.01M	10.94M
Shares Outstanding (Diluted) (Quarter)	5.01M	5.03M	5.01M	5.17M	5.31M	5.35M	5.46M	7.57M	7.61M	7.63M	7.62M	7.70M	10.30M	0.01M	0.01M	0.01M	0.01M	0.01M	0.01M	10.94M
Shares Outstanding (Entity) (Quarter)	5.02M	5.03M	5.05M	5.29M	5.32M	5.40M	5.46M	7.60M	7.62M	7.64M	7.66M	7.76M	8.31M	0.01M	0.01M	0.01M	0.01M	0.01M	0.01M
EBITDA (Quarter)	-49.05M	-43.81M	46.96M	-34.59M	-42.91M	-30.84M	-33.87M	-30.90M	-29.57M	-31.26M	-37.81M	-33.76M	-28.12M	-26.28M	-31.28M	-33.26M	-24.39M	-15.22M	-17.84M	-22.53M
Interest Expenses (Quarter)	5.00M	8.01M	2.59M	6.68M	6.31M	6.11M	20.51M	5.76M	5.78M	6.07M	2.59M	5.88M	8.95M	11.38M	11.20M	10.99M	11.23M	55.11M	12.62M	28.58M
Tax Rate (Quarter)	-0.25%	-0.21%	-0.31%	-0.32%	-0.25%	-0.12%	-0.26%	-0.16%	-0.39%	-0.03%	0.13%	-0.19%	0.28%	-0.09%	-0.24%	-0.15%	-0.11%	-0.10%	-45.79%

Research Tools

Datasets

Plans

Developers

Karyopharm Therapeutics KPTI Income Statement (2012-2026)

Research Tools

Datasets

Plans

Developers

Karyopharm Therapeutics KPTI Income Statement (2012-2026)

Create an account

Sign In

Reset Password